The gains in the global fight against tuberculosis have been threatened as a result of the COVID-19 pandemic, including a diversion of resources that have led to disruptions in ongoing research and control programs.
In a general population of patients with latent TB infection (including patients with and without HIV), studies have confirmed the superior safety profile of treatment with rifampicin vs isoniazid.
Whole genome sequencing of M tuberculosis isolates can identify complete drug susceptibility profiles, allowing precise treatment in early TB infection.
A recent trial compared the efficacy of standard oral therapy for pulmonary TB with a dry powder inhaler containing fixed doses of isoniazid, rifampicin, pyrazinamide, and levofloxacin.
Researchers studied patients with pulmonary tuberculosis to better understand the impact of sex on mortality and sputum microbiological status after treatment initiation.
Researchers conducted a phase 3 trial to ascertain whether treatment regimens including rifapentine with or without moxifloxacin can provide a lasting cure for drug-susceptible pulmonary tuberculosis in 4 months vs 6 months of standard therapy.
A retrospective cohort study was conducted to assess tolerability, side effects, and outcomes following treatment with low-dose amikacin in patients with multidrug-resistant tuberculosis.
